Impact of Anti-hyperglycemic Medications on Bone Health

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Diabetes has recently emerged as an independent risk factor for osteoporosis and osteoporotic fractures, and the underlying mechanisms are starting to be unveiled. Medications used in the treatment of diabetes may impact skeletal health in part through glycemic control. In addition, specific classes of anti-hyperglycemic medications directly influence bone metabolism. In particular, thiazolidinedione use is clearly associated with greater fracture risk. Preliminary studies suggest that medications that enhance the incretin effect (GLP-1 receptor analogs and DPP-4 inhibitors) could have a bone-protective effect, whereas SGLT-2 inhibitors could increase fracture risk. This manuscript reviews the impact of anti-hyperglycemic medications on bone health.

Original languageEnglish (US)
Pages (from-to)43-52
Number of pages10
JournalClinical Reviews in Bone and Mineral Metabolism
Volume13
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Bone and Bones
Health
Incretins
Osteoporotic Fractures
Osteoporosis
2,4-thiazolidinedione
Glucagon-Like Peptide-1 Receptor

Keywords

  • Anti-hyperglycemic
  • Diabetes
  • Fracture
  • Medications
  • Osteoporosis

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Impact of Anti-hyperglycemic Medications on Bone Health. / Maalouf, Naim M.

In: Clinical Reviews in Bone and Mineral Metabolism, Vol. 13, No. 1, 2015, p. 43-52.

Research output: Contribution to journalArticle

@article{c6db27bb78a542cd91faeb8c8e3cd6b2,
title = "Impact of Anti-hyperglycemic Medications on Bone Health",
abstract = "Diabetes has recently emerged as an independent risk factor for osteoporosis and osteoporotic fractures, and the underlying mechanisms are starting to be unveiled. Medications used in the treatment of diabetes may impact skeletal health in part through glycemic control. In addition, specific classes of anti-hyperglycemic medications directly influence bone metabolism. In particular, thiazolidinedione use is clearly associated with greater fracture risk. Preliminary studies suggest that medications that enhance the incretin effect (GLP-1 receptor analogs and DPP-4 inhibitors) could have a bone-protective effect, whereas SGLT-2 inhibitors could increase fracture risk. This manuscript reviews the impact of anti-hyperglycemic medications on bone health.",
keywords = "Anti-hyperglycemic, Diabetes, Fracture, Medications, Osteoporosis",
author = "Maalouf, {Naim M.}",
year = "2015",
doi = "10.1007/s12018-015-9176-y",
language = "English (US)",
volume = "13",
pages = "43--52",
journal = "Clinical Reviews in Bone and Mineral Metabolism",
issn = "1534-8644",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Impact of Anti-hyperglycemic Medications on Bone Health

AU - Maalouf, Naim M.

PY - 2015

Y1 - 2015

N2 - Diabetes has recently emerged as an independent risk factor for osteoporosis and osteoporotic fractures, and the underlying mechanisms are starting to be unveiled. Medications used in the treatment of diabetes may impact skeletal health in part through glycemic control. In addition, specific classes of anti-hyperglycemic medications directly influence bone metabolism. In particular, thiazolidinedione use is clearly associated with greater fracture risk. Preliminary studies suggest that medications that enhance the incretin effect (GLP-1 receptor analogs and DPP-4 inhibitors) could have a bone-protective effect, whereas SGLT-2 inhibitors could increase fracture risk. This manuscript reviews the impact of anti-hyperglycemic medications on bone health.

AB - Diabetes has recently emerged as an independent risk factor for osteoporosis and osteoporotic fractures, and the underlying mechanisms are starting to be unveiled. Medications used in the treatment of diabetes may impact skeletal health in part through glycemic control. In addition, specific classes of anti-hyperglycemic medications directly influence bone metabolism. In particular, thiazolidinedione use is clearly associated with greater fracture risk. Preliminary studies suggest that medications that enhance the incretin effect (GLP-1 receptor analogs and DPP-4 inhibitors) could have a bone-protective effect, whereas SGLT-2 inhibitors could increase fracture risk. This manuscript reviews the impact of anti-hyperglycemic medications on bone health.

KW - Anti-hyperglycemic

KW - Diabetes

KW - Fracture

KW - Medications

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=84925533456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925533456&partnerID=8YFLogxK

U2 - 10.1007/s12018-015-9176-y

DO - 10.1007/s12018-015-9176-y

M3 - Article

AN - SCOPUS:84925533456

VL - 13

SP - 43

EP - 52

JO - Clinical Reviews in Bone and Mineral Metabolism

JF - Clinical Reviews in Bone and Mineral Metabolism

SN - 1534-8644

IS - 1

ER -